EU-Japan Biotech & Pharma Partnering Conference 2026

16 Sept – 5 Oct 2026 | Osaka, Japan

HomeAgenda
Register
Register
Register

ProductUpdated on 2 September 2026

EAD1662 for the treatment of Alopecia

About

EAD1662 is potential therapeutics for Alopecia based on the mechanisms of protecting HFSCs (Hair Follicle Stem Cells) and enhancing the growth of HFSCs.

EADERM is conducting the GLP toxicology studies of EAD1662, and the Phase1 study for Alopecia Areata has planned in Japan for 2028.

We are seeking a partner to develop and commercialize EAD1662 worldwide.

Organisation

EADERM Co., Ltd.

Company (SME/startup) / 中小企業・スタートアップ

Tokyo, Japan

Similar opportunities